Spetty,
but again failed to mention the single-blastomere technology (even though it's not being used for this trial).
If some of these reporters were up to speed, which many are not, would it be better to have them say something like the following?
(example)
ACTC has patented single blastomere technology that does NOT harm the embryo. The upcoming trials will be using a single blastomere derived hESC line, MA09, which did NOT preserve the embryo.
My point, I am hoping updated news of trials and the no destructiion process stay seperated unless ACT educates via their own PR's. I haven't gone back to look at all clinical trial updates but "single blastomere" is not a part of the lingo but rather ..."using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).....I suspect for the same reason I am trying to make...thanks
